LY-344545: Difference between revisions

Revision as of 11:25, 23 January 2023 editEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,831 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper ← Previous edit		Latest revision as of 19:32, 20 December 2023 edit undoJJMC89 bot III (talk \| contribs)Bots, Administrators3,684,692 editsm Moving Category:Eli Lilly and Company brands to Category:Drugs developed by Eli Lilly and Company per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands
Line 52:		Line 52:
	{{Metabotropic glutamate receptor modulators}}		{{Metabotropic glutamate receptor modulators}}

	]		]
	]		]
	]		]

Latest revision as of 19:32, 20 December 2023

Chemical compound Pharmaceutical compound

LY-344545
Identifiers

IUPAC name (αS)-α-Amino-α--9H-xanthene-9-propanoic acid
CAS Number	201851-20-9
PubChem CID	10618042
ChemSpider	8793407
UNII	9ZSQ1C4209
Chemical and physical data
Formula	C₂₀H₁₉NO₅
Molar mass	353.374 g·mol
3D model (JSmol)	Interactive image
SMILES c1ccc2c(c1)C(c3ccccc3O2)C(4C4C(=O)O)(C(=O)O)N
InChI InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20+/m1/s1 Key:VLZBRVJVCCNPRJ-RCDCFZSISA-N
(verify)

LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR₅. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR_2/3-selective LY-341,495.

Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, et al. (January 1998). "2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability". Journal of Medicinal Chemistry. 41 (3): 358–78. doi:10.1021/jm970498o. PMID 9464367.
Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, et al. (September 2000). "A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices". British Journal of Pharmacology. 131 (2): 239–44. doi:10.1038/sj.bjp.0703574. PMC 1572327. PMID 10991916.

mGluR₁Tooltip Metabotropic glutamate receptor 1

mGluR₅Tooltip Metabotropic glutamate receptor 5

mGluR₂Tooltip Metabotropic glutamate receptor 2

mGluR₃Tooltip Metabotropic glutamate receptor 3

mGluR₄Tooltip Metabotropic glutamate receptor 4	Agonists: Glutamate L-AP4 LSP2-9166 PHCCC VU-001,171 VU-0155,041; Positive allosteric modulators: Foliglurax MPEP Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112
mGluR₆Tooltip Metabotropic glutamate receptor 6	Agonists: Glutamate L-AP4 Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112
mGluR₇Tooltip Metabotropic glutamate receptor 7	Agonists: AMN082 Glutamate L-AP4 LSP2-9166 Antagonists: CPPG MAP4 MMPIP MPPG MSOP MTPG UBP-1112 XAP044; Negative allosteric modulators: ADX71743
mGluR₈Tooltip Metabotropic glutamate receptor 8	Agonists: DCPG Glutamate L-AP4; Positive allosteric modulators: AZ12216052 Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112

See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.